VivoSeq
Oncology

Renal Cancer

1

Pipeline Programs↗

6

Active Trials↗

5

Companies Involved↗

Renal Cancer is an early-stage landscape with 1 program across 5 companies. The most active players are Novartis, Five Eleven Pharma, Inc., Bayer.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalF

Five Eleven Pharma, Inc.

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalRoche logo

Roche

0 programs

PreclinicalH

HistoSonics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

124icg250

Memorial Sloan Kettering Cancer Center

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

23

clinical trials

Completed12 · 52%
Active, not recruiting4 · 17%
Unknown status3 · 13%
Terminated2 · 9%
Recruiting2 · 9%

Clinical Trials

Trial Activity

23 trials

A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients with Colorectal, Ovarian, and Renal Cancers
Recruiting·AAurigene Discovery Technologies Limited·Phase 2·NCT06760702·90 enrolled
Advanced Diffusion Imaging in Renal Cancer Patients
Recruiting·NNYU Langone Health·N/A·NCT06116253·90 enrolled
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
Active, not recruiting·PProvidence Health & Services·Phase 2·NCT02306954·84 enrolled
Pilot Trial To Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT01582204·17 enrolled
Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT01888198·294 enrolled
The HistoSonics Edison System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY US)
Active, not recruiting·HHistoSonics, Inc.·Preclinical·NCT05820087·67 enrolled
Sunitinib in Metastatic Renal Cancer
Completed·IIstituto Clinico Humanitas·Phase 2·NCT01034878·25 enrolled
Pilot Study of Denileukin Diftitox Plus High-Dose IL-2 for Patients With Metastatic Renal Cancer
Completed·NNorthwestern University·Phase 1·NCT00278369·20 enrolled
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Completed·Novartis logoNovartis·Phase 1·NCT03798626·167 enrolled
The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer
Completed·—·N/A·NCT02404584·43 enrolled
Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer
Completed·FFive Eleven Pharma, Inc.·Phase 1·NCT03073395·30 enrolled
Nexavar Dosing in Renal Cancer Patients in "Real-life" Setting
Completed·Bayer logoBayer·N/A·NCT01557127·205 enrolled
A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer
Completed·National Cancer Institute (NCI)·Phase 1·NCT00001570·46 enrolled
Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer
Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT01751529·48 enrolled
Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion
Completed·SScottish Clinical Trials Research Unit·Phase 2·NCT03494816·24 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)